Aldeyra Therapeutics, Inc. ALDX
1.21
(0.01)
(0.82%)
as of 25 Sep
- Market cap
- $73.6M
- P/E
- 0.0×
Follow ALDX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.72 | 2.58 | 2.72 | 4.91 |
Net Debt/EBITDA |
7.33 | 8.24 | 14.28 | 7.80 | |
Debt/Assets |
19.54% | 21.16% | 23.01% | 0.00% | |
Debt/Equity |
0.31 | 0.34 | 0.36 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 0.82 | 1.48 | 0.84 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.33) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.12) | (0.09) | (0.08) | (0.08) | |
Cash per Share |
1.25 | 1.17 | 1.08 | 0.75 | |
Shareholders Equity per Share |
0.82 | 0.74 | 0.70 | 0.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 0.74 | 0.70 | 0.63 | |
Free Cash Flow |
(7.02) | (5.30) | (5.11) | (4.61) | |
Working Capital |
48.98 | 43.97 | 41.95 | 37.72 | |
Capital Expenditures |
— | — | — | (0.02) | |
Net Current Asset Value |
48.90 | 43.97 | 41.95 | 37.72 | |
| Other line items | |||||
Quick Ratio |
2.64 | 2.52 | 2.67 | 4.67 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.12) | (0.09) | (0.08) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.10 | 0.17 | 0.24 | 0.80 | |
Average Assets |
97.56 | 88.33 | 79.84 | 66.25 | |
Average Common Equity |
67.17 | 57.63 | 52.88 | 46.59 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates